[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and...

{
  "signal_id": "76f9a6e0-25cc-6f02-9907-8a1e7f3d005c",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-09-22T05:00:00+00:00",
  "company": {
    "name": "Roche",
    "domain": "roche.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/09/22/3365947/0/en/ad-hoc-announcement-pursuant-to-art-53-lr-roche-announces-positive-phase-ii-results-for-dual-glp-1-gip-receptor-agonist-enicepatide-in-people-living-with-type-2-diabetes-and-overwe.html",
    "title": "[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity",
    "excerpt": "Basel, 22 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced positive topline results from CT-388-104, a Phase II clinical trial evaluating enicepatide (CT-388), an investigational, once-weekly dual GLP-1/GIP receptor agonist, in adults living with type 2 diabetes (T2D) and overweight or obesity. In the study, enicepatide met both primary endpoints, delivering dose-dependent and clinically meaningful reductions in blood glucose and body weight at 48 weeks. Patients receiving the highest titrated dose (24 mg) achieved an HbA1c reduction of 2.65% (from a baseline HbA1c of 8.1%). Furthermore, 90% of patients in the 24 mg cohort reached an HbA1c level of ≤6.5% (diagnostic threshold for T2D) and 62% achieved normoglycemia (HbA1c < 5.7%), restoring blood glucose levels to a non-diabetic range. The mean weight loss at 48 weeks in the 24 mg enicepatide arm was 15.5% without a demonstrable plateau.",
    "product": "enicepatide",
    "summary": "Roche announced positive topline results from a Phase II clinical trial for its investigational drug enicepatide (CT-388), a dual GLP-1/GIP receptor agonist for adults with type 2 diabetes and overweight or obesity.",
    "location": "Basel, Switzerland",
    "planning": true,
    "confidence": 0.95,
    "product_data": {
      "name": "enicepatide",
      "full_text": "enicepatide (CT-388), an investigational, once-weekly dual GLP-1/GIP receptor agonist",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-09-22T05:00:00Z",
    "location_data": [
      {
        "city": "Basel",
        "state": "Basel-Stadt",
        "region": "Western Europe",
        "country": "Switzerland",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-09-22",
    "article_sentence": "Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced positive topline results from CT-388-104, a Phase II clinical trial evaluating enicepatide (CT-388), an investigational, once-weekly dual GLP-1/GIP receptor agonist, in adults living with type 2 diabetes (T2D) and overweight or obesity."
  }
}

curl https://signals.autobound.ai/v1/signals/76f9a6e0-25cc-6f02-9907-8a1e7f3d005c \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"roche.com","limit":20}'